Novosti
Khirurgii

 This journal is
indexed in Scopus
journal cover
android icon Android Applicaion

Year 2007 Vol. 15 No 1

REVIEWS

SPIRIDONOV S.V.

MODERN POSSIBILITIES OF OPERABLE NON SMALL-CELLED III DEGREE LUNG CANCER TREATMENT

By the beginning of the 21st century in the majority of the developed countries the tendency in performing oncology surgeries in case of lung cancer had begun to appear in large regional multi-profile centers on the basis of cardio-thoracic departments. It permits to extend lung cancer surgical treatment possibilities and possibilities for accompanying cardiac diseases treatment (coronary artery shunting, aneurism resection) using the latest cardio-surgery achievements such as performing operations with the artificial blood circulation or even with the lung transplantation. But the results of the surgical intervention alone in case of IIIA or IIIB degree of non small-celled lung cancer are not very satisfactory. If the patient isn’t refused surgery, the treatment of this patient should be planned with the compulsory additional usage of chemotherapy and radiotherapy. The recent researches haven’t shown the positive effect of the post-operative radiotherapy on the life length increase. Some researches have established that in 80% of cases, the main cause of death after radical operation in case of non small-celled III degree lung cancer is the progressing process with distant metastasis. That’s why the interest of oncologists to systemic influence on the tumor is rather clear. During the last 3 years five researches have been conducted which testify to adjuvant chemotherapy positive effect and its everyday wider application expediency. However, there are many unsolved problems concerning practical application of adjuvant chemotherapy. What chemotherapy is optimal according to its toxicity and effectiveness? What patients are to undergo adjuvant chemotherapy?

Keywords: non small-celled lung cancer, adjuvant radiotherapy, adjuvant chemotherapy.
p. 103 - 109 of the original issue
References
  1. Значение адьювантной лучевой терапии при хирургическом лечении больных НМРЛ / А. С. Барчук [и др.] // Вопр. онкол. – 1998. – №2. – С. 159-163.
  2. Давыдов, М. И. Рак легкого / М. И. Давыдов, Б. Е. Полоцкий. – М.: Радикс, 1994.
  3. Жарков, В. В. Комбинированное лечение больных немелкоклетечным раком легкого III ст.(N2) стадии с адьювантной терапией / В. В. Жарков, В. П. Курчин, С. В. Спиридонов // IV Съезд онкологов и радиологов СНГ. – Баку, 2006. – С.109.
  4. Павлов, А. С. Лечение рака легкого / А. С. Павлов, А. И. Пирогов, А. Х. Трахтенберг. – М.: Медицина, 1979. – 312 с.
  5. Рукосуев, А. А. Медиастинальна лимфодиссекция при хирургическом лечении больных немелкоклеточным раком легкого / А. А. Рукосуев, А. Х. Трахтенберг, Е. В. Котляров // Торакальная онкохирургия / под. ред. В. И. Чиссова [и др.]. – М., 1994. – С. 65–75.
  6. Тер-Ованесов, М. Д. Достижение в онкохирургии начала 21 века / М. Д. Тер-Ованесов, А. К. Тойгонденов, В. А. Марчук // Практическая онкология. – 2005. – Т.6, №1.
  7. Лечение рака легкого / В. П. Харченко [и др.] // Вопр. Онкол. – 1999. – №2. – С.184-187.
  8. Brunner, K. W. Effects of long–term adjuvant chemotherapy with cyclophosphamide for radically resected bronchogenic carcinoma / K. W. Brunner, T. Marthalar, W. Muller // Cancer Chemother. Rep. – 1973. – Vol. 4. – P. 125–127.
  9. Clinical analysis of small–sized peripheral lung cancer / T. Koike [et al.] // J. Thorac. Cardiovasc. Surg. – 1998. – Vol. 115. – P. 1015–1120.
  10. ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association / J. Y. Douillard [et al.] // Proc. Am. Soc. Clin. Oncol. – 2005. – Vol. 23. – Abstr. 7013. – P. 624
  11. Five year follow up of cytotoxic chemotherapy as an adjuvant to surgery in carcinoma of the bronchus / H. Scott [et al.] // Br. J. Cancer. – 1976. – Vol. 34, №2. – P. 167–173.
  12. Chemoradiation therapy versus chemotherapy alone as a neoadjuvant treatment for stage III non–small cell lung cancer. Preliminary report of a phase III prospective randomised trial. / J. Fleck [et al.] // Proc. Am. Soc. Clin. Oncol. – 1993. – Vol. 12. – P.333.
  13. Recurrence of bronchioloalveolar carcinoma in transplanted lungs / R. I. Garver [et al.] // New Engl. J. Med. – 2001. – Vol.340, N 14. – P. 1071-1074.
  14. The use of cardiopulmonary bypass during extehded resection of njn-small cell lung cancer / S. Hasegawa [et al.] // Int. Thorac. Cardiovasc. Sugr. –2004. – P.676-679.
  15. Hughes, R. A. Veterans’ surgical adjuvant lung cancer chemotherapy study, present status / R. A. Hughes, G. A. Higgins // J. Thorac. Cardiovasc. Surg. – 1962. – Vol. 44. – P. 295–299.
  16. For the IALT Investigators. Results of the randomized international adjuvant lung cancer trial (IALT): cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC) / T. Le Chevalier // Proc. Am. Soc. Clin. Oncol. – 2003. – Vol.22, N 3.
  17. Le Chevalier T. Results of the randomized international adjuvant lung cancer trial (IALT) cisplatin-based chemotherapy versus no chemotherapy in 1867 patients with resected non-small cell lung cancer / T. Le Chevalier // Proc. ASCO. – 2003. – Vol. 22, N 2. – Abstr. 6.
  18. Phase III study of amifostine in patients with locally advanced non-small cell lung cancer (NSCLC) receiving chemotherapy & hyperfractionated radiation (chemo/HFxRT): Radiation Therapy Oncology Group (RTOG) 98-01. / B. Movsas [et al.] // Proc. Am. Soc. Clin. Oncol. – 2003. – Vol. 22, N 636. – Abstr. 2559.
  19. Cardiopylmonary bypass during pulmonare sugery / W. E. Neville [et al.] // J. Thorac. Cardiovasc. Sugr. – 1965. – Vol.50. – P.693-699.
  20. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials // BMJ. – 1995. – Vol. 311. – P. 899-909.
  21. The epidemiology of small cell lung cancer / N. Page [et al.] // Program and abstracts of the American Society of Clinical Oncology 38th Annual Meeting, 2002, May 18-21, Orlando, Florida. – Abstr. 1216.
  22. PORT meta-analysis trialists group: postoperative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials // Lancet. – 1998. – Vol.352. – P. 257-263.
  23. Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma lung / T. W. Shields [et al.] // Cancer. – 1982. – Vol. 50. – P. 1713–1722.
  24. Scbrump, D. Cardiopulmonary bypass for extended resection of thoracic malignancies / D. Scbrump // Advanced therapy in thoracic surgery / R. Franco, J. Putanam; ed.B. C. Decker. – 1998. – P.238-246.
  25. Shields, T. W. Bronchocarcinoma treated by adjuvant cancer chemotherapy / T. W. Shields, C. D. Robinette, R. J. Keehn // Arch. Surg. – 1974. – Vol. 109. – P. 329–331.
  26. Significance of metastatic disease in subaortic lymph nodes / G. A. Patterson [et al.] // Ann. Thorac. Surg. – 1987. – Vol. 43. – P. 155–159.
  27. Slack, H. H. Bronchogenic carcinoma: nitrogen mustard as a surgical adjuvant and factors influencing survival. University Surgical Adjuvant Lung Cancer Project / H. H. Slack // Cancer. – 1970. – Vol. 25. – P. 987–993.
  28. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC) Report of Cancer and Leukemia Group B (CALGB) Protocol 9633 / G. Strauss [et al.] // Proc. ASCO. – 2004. – Vol.23, N 17. – Abstr. 7019.
  29. The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node invovement / T. E. Sawyer [et al.] // Cancer. – 1997. – Vol. 80. – P. 1399–1408.
  30. Extended resection of the left atrum, great vessels, or both for lung cancer / R. Tsuchiva [et al.] // Ann. Thorac. Sugr. – 1994. –Vol.57. – P.960-965.
  31. Van Houtte, P. Limites et perspectives de la radiotherapie postoperatoire dans le cancer bronchique / P. Van Houtte, F. Mornex, P. Rocmans // Cancer Radiother. – 1998. – Vol. 2. – P. 252–259.
  32. Van Houtte, P. Postoperative irradiation for lung cancers: indications, technical issues and perspectives (meeting abstract) / P. Van Houtte // International Congress of Radiation Oncology, 1993, Japan, June 21–25. – P. 143.
  33. Weisenburger, T. H. The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung / T. H. Weisenburger, M. Gail // N. Engl. J. Med. – 1986. – Vol. 315. – P. 1377–81.3.
  34. A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage IB and II non-small cell lung cancer (NSCLC) Intergroup JBR.10 / T. Winton [et al.] // Proc. ASCO. – 2004. – Vol. 23, N 17. – Abstr. 7018.
Contacts | ©Vitebsk State Medical University, 2007-2023